The 9th edition of PharmaMed 2026, organized by the PHD Chamber of Commerce & Industry in collaboration with the Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers, Government of India, concluded in New Delhi today. Following a high-impact inaugural session in the morning, the conference featured four thematic sessions, where industry leaders, policymakers, regulators, and stakeholders engaged in in-depth deliberations on key priority areas shaping the future of India’s pharmaceutical sector.

The discussions underscored India’s transition from a volume-driven to a value-driven pharmaceutical ecosystem, with a strong focus on innovation, quality, resilience, and last-mile access.

Speakers highlighted the need to drive innovation in high-value pharmaceuticals, biologics, and advanced therapies while building robust capabilities in biosimilars and biopharmaceutical manufacturing.

Session on ‘Redefining India’s Pharmaceutical Leadership - From Volume to Value’ witnessed participation from CDSCO, PharmaExil, Cipla, NIPER. It focused on shifting India’s pharmaceutical sector toward high-value innovation. Discussions emphasized strengthening research in biologics, advanced therapies, and biosimilars, while aligning academic research with industry and regulatory needs. The importance of integrating quality from the early stages and balancing innovation with affordability to maintain global competitiveness was stressed by the speakers.

Delegates stressed on improving quality standards across the supply chain through stronger regulatory frameworks and compliance in the session on ‘Strengthening Pharmaceutical Quality – Regulatory Harmonization & Global Compliance’ . They also underscored the need for harmonization between central and state regulations, adoption of global standards, enhanced pharmacovigilance, and the use of digital tools such as AI and traceability systems to ensure end-to-end quality assurance.

Session on ‘Supply Chain Challenges in Pharma & Tackling Counterfeit Drugs’ had speakers from Mankind Pharma, Safeexpress Private. They stressed the need to reduce dependence on imports for APIs and raw materials while strengthening domestic manufacturing. The session also highlighted improving logistics, cold chain infrastructure, and workforce skills. The role of technology, especially AI, in optimizing supply chains and combating counterfeit drugs was emphasized.

Session on ‘Last-Mile Access to Medicines – Strengthening Distribution & Affordability,’ focused on improving access to medicines through digital transformation and efficient distribution systems. Discussions highlighted the growing role of e-pharmacies, the need for balanced regulation, and the importance of ensuring affordability and accessibility to achieve healthcare equity across the country.

Leading organizations and industry stakeholders, including Central Drugs Standard Control Organization, Pharmexcil, Cipla, AstraZeneca, Organisation of Pharmaceutical Producers of India, Serum Institute of India, Biotechnology Industry Research Assistance Council, National Institute of Pharmaceutical Education and Research Mohali, United States Food and Drug Administration, Tenet Health Edutech Pvt Ltd, NuLifeCare, Daund Biological, EVERSANA, Jamia Hamdard, Mankind Pharma, Apollo Pharmacy, Tata 1mg, and Association of Healthcare Providers India actively participated in the sessions, contributing diverse expertise and valuable insights through the sessions.

Overall, PharmaMed 2026 highlighted India’s commitment to building a future-ready pharmaceutical sector that balances innovation with inclusivity. The conference reinforced that achieving healthcare equity will require coordinated efforts across academia, industry, and government, ensuring that high-quality, affordable medicines reach every citizen while strengthening India’s global leadership in pharmaceuticals.

 

****

 

PC/PM

(Release ID: 2246290) Visitor Counter : 237